In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zooming From Zero To $400 Million: The Making of Mankind Pharma - India’s Fastest Growing Company

This article was originally published in The Pink Sheet Daily

Executive Summary

The head of India’s fastest-rising pharma company may be unconventional, but his willingness to take risks and do business differently has set the company on an upward trajectory.

You may also be interested in...



Global Pharma Bidders May Queue Up For A Slice Of Mankind Pharma And Scorching 25 Percent Growth

MUMBAI - India's Mankind Pharma, which has seen exponential year-on-year growth of more than 25 percent, may be the latest attraction for large multinational pharma companies as speculation gathers steam that its deep roots in the largely untapped semi-urban and rural markets makes it an enviable takeover target

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS073244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel